Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KTTABullishIndustry Newsnews

High materiality7/10

KTTA may leverage PAS-004 durability data as near-term catalyst

Oct 23, 2026, 5:50 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive early durability and favorable safety signals can re-rate a small biotech’s pipeline, but the small patient subset limits certainty; still, near-term catalysts typically accompany such disclosures when linked to a sponsor's program.

AI summary

What happened, with direct paths to the underlying reporting

PAS-004 produced prolonged stable disease in heavily pre-treated patients, including four beyond 300 days and two beyond 500 days in BRAF V600E melanoma after prior dabrafenib/trametinib. The safety profile appears favorable, supporting longer treatment duration. For KTTA, these signals could serve as a near-term catalyst and de-risk future trials if PAS-004 is KTTA's program.

PAS-004 achieved prolonged stable disease in heavily pre-treated patients. Positive durability signals.
Four patients on PAS-004 >300 days; two >500 days on treatment.
Melanoma with BRAF V600E; prior progression on dabrafenib/trametinib.
Overall long-term tolerability appears favorable in the heavily pre-treated population.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

KTTA may leverage PAS-004 durability data as near-term catalyst

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results